Literature DB >> 22294369

Cyclic nucleotide phosphodiesterase assay technology.

S J MacKenzie1, S F Hastings, C Wells.   

Abstract

Because of their critical role in modulating cellular cyclic nucleotide levels, phosphodiesterases (PDEs) are involved in many disease-related signaling pathways. The PDE family is large and diverse, with members having different tissue distribution, sub-cellular localizations, and substrate specificities. Because of these characteristics, the PDEs represent a broad group of potential drug targets. Described in the present unit are the assay development and validation procedures needed to establish a high-throughput screening system for these important enzymes. The assays provide a structured approach for determining the kinetic parameters of related enzyme families to facilitate the characterization of PDE inhibitors.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 22294369     DOI: 10.1002/0471141755.ph0312s49

Source DB:  PubMed          Journal:  Curr Protoc Pharmacol        ISSN: 1934-8282


  1 in total

1.  The atypical anxiolytic drug, tofisopam, selectively blocks phosphodiesterase isoenzymes and is active in the mouse model of negative symptoms of psychosis.

Authors:  Chris Rundfeldt; Katarzyna Socała; Piotr Wlaź
Journal:  J Neural Transm (Vienna)       Date:  2010-10-22       Impact factor: 3.575

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.